Newtyn Management, LLC T Scan Therapeutics, Inc. Transaction History

Newtyn Management, LLC

  • $567 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$1.66 - $3.32 $11,288 - $22,576
6,800 Added 2.96%
236,800 $497,000
Q4 2022

Feb 14, 2023
BUY
$1.49 - $3.33 $44,700 - $99,900
30,000 Added 15.0%
230,000 $356,000
Q3 2022

Nov 14, 2022
SELL
$2.62 - $4.39 $127,360 - $213,402
-48,611 Reduced 19.55%
200,000 $610,000
Q2 2022

Aug 15, 2022
BUY
$1.65 - $3.58 $410,208 - $890,027
248,611 New
248,611 $782,000

Others Institutions Holding TCRX

# of Institutions
89
Shares Held
41.8M
Call Options Held
0
Put Options Held
0
View Full List

About TScan Therapeutics, Inc.

TCRX Quotes by TradingView
  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $57.9M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Newtyn Management, LLC Portfolio

Follow Newtyn Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Newtyn Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Newtyn Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email